聚焦肺癌免疫治疗，核心探索 PD-1/VEGF 双抗等新型免疫药物的原发耐药机制（如 PPIA-CD147 轴调控）与逆转策略，同步开展新型免疫药物临床研究。

Focus on lung cancer immunotherapy, with core research including exploring primary resistance mechanisms (e.g., PPIA-CD147 axis regulation) and reversal strategies of novel immunotherapeutics like PD-1/VEGF bispecific antibodies, while simultaneously conducting clinical studies of new immunotherapeutic drugs.

中国临床肿瘤学会非小细胞肺癌专委会委员

中国抗癌协会罕见突变及罕见肿瘤专委会委员

中国抗癌协会个案管理专业委员会委员

上海抗癌协会肿瘤呼吸内镜专委会委员

Frontiers in Cell and Developmental Biology、AJTR、AJCR 等杂志审稿人

________________________________________

Member of Non-Small Cell Lung Cancer Committee, Chinese Society of Clinical Oncology (CSCO)

Member of Rare Mutation and Rare Tumor Committee, Chinese Anti-Cancer Association (CACA)

Member of Case Management Professional Committee, Chinese Anti-Cancer Association (CACA)

Member of Thoracic Endoscopy Committee for Tumors, Shanghai Anti-Cancer Association

Reviewer for journals including Frontiers in Cell and Developmental Biology, AJTR, AJCR

【研究方向】长期聚焦肺癌免疫治疗临床与转化研究，核心方向为 PD-1/VEGF 双抗等新型免疫药物的原发耐药机制（如 PPIA-CD147 轴调控）、逆转策略开发及临床转化，同步开展 CTC 诊断相关转化医学研究。

【科研项目】主持国家自然科学基金、CSCO 临床基金等课题，经费支持充足，研究平台成熟。

【学术成果】发表 SCI 论文 30 余篇，成果见于 Lancet（IF=98.4）、Journal of Clinical Oncology（IF=42.1）等国际顶级期刊；主编《实体肿瘤 CAR-T 治疗免疫学基础和临床研究探索》专著 1 部，研究为肺癌免疫治疗优化提供关键理论支撑。

【临床研究】牵头/核心参与 HARMONi-2、GEMSTONE-302 等多项重大临床研究，推动依沃西单抗等药物成为肺癌一线治疗新选择，具备丰富的临床研究设计与实施经验。

Research Focus: Long-term commitment to clinical and translational research in lung cancer immunotherapy. Core directions include exploring primary resistance mechanisms of novel immunotherapeutics (e.g., PD-1/VEGF bispecific antibodies) such as PPIA-CD147 axis regulation, developing reversal strategies and clinical translation, as well as conducting translational medical research on CTC diagnosis.

Funded Projects: Principal investigator of multiple projects, including those supported by the National Natural Science Foundation of China (NSFC) and CSCO Clinical Research Fund, with sufficient funding and well-established research platforms.

Academic Achievements: Published over 30 SCI-indexed papers in top international journals like Lancet (IF=98.4) and Journal of Clinical Oncology (IF=42.1); Editor-in-Chief of one monograph titled "Immunological Basis and Clinical Research Exploration of CAR-T Therapy for Solid Tumors". Relevant research provides critical theoretical support for optimizing lung cancer immunotherapy.

Clinical Trials: Led or core participated in major clinical trials such as HARMONi-2 and GEMSTONE-302, promoting drugs like Ivonescimab as new first-line treatment options for lung cancer, with extensive experience in clinical research design and implementation.